comprehensive -WSS

comprehensive

author：hotspot 2025-10-01 23:05:46 - browse：61639

Sammy Kimball for STAT

Can Novavax finally get it right? What’s a “triple-G” drug? And is Novo Nordisk losing ground?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Elaine Chen joins us to explain how the era of Wegovy could be short-lived in light of powerful new weight-loss medicines from Eli Lilly. Then, John Jacobs, the new CEO of Novavax, stops by to explain his plan to right the ship at a company that has struggled to make the most of its potent Covid-19 vaccine.

For more on what we cover, here’s the news on Lilly; here’s more on Novavax; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Supreme Court strikes down use of affirmative action
Next article： Measles policy set amid Florida outbreak alarms vaccine proponents

WSS

Acelyrin, a rare IPO success, stumbles in its first big test

Reporting on presidential health from Reagan to Trump and Biden

Private equity could exacerbate cardiology's overuse problem, experts fear

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Ukraine seeks to reclaim its role as a hub for clinical trials

Regeneron agrees to White House price limits on anti

Wikipedia

comprehensive

explore

DIEP, the 'gold standard' of breast reconstruction, is under threat

IRA could hurt research into orphan drugs for rare diseases

Hepatitis C has a cure — but many Americans still lack access to it

A new drug could help frostbite victims avoid its ravages

Guidelines to prevent youth baseball injuries need more muscle

Walmart eyes Medicare Advantage provider ChenMed

Peter Hotez and the public health issue of online harassment

Food makers to regulators: Ultra

23andMe had bad news about my health. I wish a person had delivered it

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

focus

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Telehealth for opioid use disorder is lifesaving

A common UTI test for kids haunts adults as a traumatic 'nightmare'

Generate Biomedicines machine learning biotech raises $273M

Measles policy set amid Florida outbreak alarms vaccine proponents

Generate Biomedicines machine learning biotech raises $273M

focus

hotspot

focus

focus